Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Verdiperstat on Microglial Activation in MSA
NCT04616456Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verdiperstat in multiple system atrophy (MSA), sponsored by Brigham and Women's Hospital. Primary endpoints: Standardized Uptake Values at 1 month and Standardized Uptake Ratios at 1 month. Started Dec 2020; status: completed.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04616456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616456.